Cancer Research UK has teamed up with MSD (Merck) and the Wellcome Trust to co-develop some Inhibitors for both Cancerous and Non-cancerous blood disorders from the Australian Academia-Biotech Network.
CTx is collaborative partnership of leading Research Institutes, Universities and biotechs that translates Australia’s innovative research discoveries into new cancer drugs ready for clinical development.
And these inhibitors have now caught the attention of some of the European leaders in Cancer Research, including the Wellcome Trust Seeding Drug Discovery Program (UK) and the Biopharma Giant, MSD (Germany).
Cancer Research Technology (CRT) is a wholly owned subsidiary of Cancer Research UK. CRT has now ‘brokered’ the licensing rights for the Aussie inhibitor program to Germany’s MSD, for which CRT will receive $15M (€13.8M), in addition to potential milestone-regulated payments of up to €460M.